167 related articles for article (PubMed ID: 33900646)
21. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
22. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
23. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer.
Hirahara T; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kita Y; Mori S; Sasaki K; Omoto I; Kurahara H; Maemura K; Okubo K; Uenosono Y; Ishigami S; Natsugoe S
BMC Cancer; 2019 Jul; 19(1):672. PubMed ID: 31286873
[TBL] [Abstract][Full Text] [Related]
24. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.
Koo KC; Lee JS; Ha JS; Han KS; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
World J Urol; 2019 Nov; 37(11):2375-2384. PubMed ID: 30734074
[TBL] [Abstract][Full Text] [Related]
25. The relationship between platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience.
Dogan M; Eren T; Ozdemir N; Cigirgan CL; Zengin N
Saudi J Gastroenterol; 2015; 21(5):320-4. PubMed ID: 26458860
[TBL] [Abstract][Full Text] [Related]
26. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
[TBL] [Abstract][Full Text] [Related]
27. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival.
Cummings M; Merone L; Keeble C; Burland L; Grzelinski M; Sutton K; Begum N; Thacoor A; Green B; Sarveswaran J; Hutson R; Orsi NM
Br J Cancer; 2015 Jul; 113(2):311-20. PubMed ID: 26079303
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities.
Chen Z; Zhao G; Chen F; Xia J; Jiang L
BMC Cancer; 2019 Apr; 19(1):329. PubMed ID: 30961549
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer.
Sun Z; Ju Y; Han F; Sun X; Wang F
J Clin Lab Anal; 2018 Mar; 32(3):. PubMed ID: 28605139
[TBL] [Abstract][Full Text] [Related]
30. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?
Solmaz Medeni S; Acar C; Olgun A; Acar A; Seyhanlı A; Taskıran E; Sevindik OG; Alacacıoglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
Clin Transplant; 2018 Sep; 32(9):e13359. PubMed ID: 30053318
[TBL] [Abstract][Full Text] [Related]
31. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
[No Abstract] [Full Text] [Related]
32. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
34. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
35. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
[TBL] [Abstract][Full Text] [Related]
36. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer.
Cong R; Kong F; Ma J; Li Q; Wu Q; Ma X
BMC Cancer; 2020 May; 20(1):464. PubMed ID: 32448185
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
38. Preoperative Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Associated with the Prognosis of Group 3 and Group 4 Medulloblastoma.
Li K; Duan WC; Zhao HB; Wang L; Wang WW; Zhan YB; Sun T; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZF; Zhang ZY
Sci Rep; 2019 Sep; 9(1):13239. PubMed ID: 31519974
[TBL] [Abstract][Full Text] [Related]
39. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
40. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.
Templeton AJ; Pezaro C; Omlin A; McNamara MG; Leibowitz-Amit R; Vera-Badillo FE; Attard G; de Bono JS; Tannock IF; Amir E
Cancer; 2014 Nov; 120(21):3346-52. PubMed ID: 24995769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]